

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: Treatment.com International Inc. ("the "Issuer").

Trading Symbol: TRUE

Number of Outstanding Listed Securities: 66,186,820

Date: May, 2022

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On May 18, the Issuer announced the closing of a non-brokered private placement, raising aggregate gross proceeds of \$340,000 in unsecured convertible debentures (the "Private Placement").

2. Provide a general overview and discussion of the activities of management.

Management has been working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights through Cara, an innovative mobile app powered by this exclusive AI engine.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

This section is not applicable to the Issuer.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This section is not applicable to the Issuer.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

This section is not applicable to the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

This section is not applicable to the Issuer.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or

disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

This section is not applicable to the Issuer.

8. Describe the acquisition of new customers or loss of customers.

This section is not applicable to the Issuer.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

This section is not applicable to the Issuer.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This section is not applicable to the Issuer.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This section is not applicable to the Issuer.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This section is not applicable to the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

This section is not applicable to the Issuer.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Convertible Debentures	400	(2)	\$340,000 – General Working Capital

(1) State aggregate proceeds and intended allocation of proceeds.

- (2) Pursuant to the Private Placement. Each Debenture at a price of \$1,000 per Debenture, less a 15% discount. The Debentures bear interest at a rate of 8.00% per annum, accruing on a semi-annual basis and payable, in cash or units of the Company (the “Units”), every 6 months from the date of issue, maturing 24 months from the date of issue. Each Unit will consist of one common share in the capital of the Company (a “Share”) and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at a price of \$0.50 per Warrant Share for a period of two years following the issue date.
15. Provide details of any loans to or by Related Persons.
This section is not applicable to the Issuer.
16. Provide details of any changes in directors, officers or committee members.
This section is not applicable to the Issuer.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.
This section is not applicable to the Issuer.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 2, 2022

John Fraser
Name of Director or Senior Officer

“John Fraser”
Signature

CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer Treatment.com International Inc.	May	YY/MM/D 22/06/02

FORM 7 – MONTHLY PROGRESS REPORT

Issuer Address 700-838 W Hastings Street		
City/Province/Postal Code Vancouver, BC, V6C 0A6	Issuer Fax No. n/a	Issuer Telephone No. (612) 788-8900
Contact Name John Fraser	Contact Position CEO	Contact Telephone No. (612) 788-8900
Contact Email Address: jf@treatment.com	Web Site Address https://treatment.com	